Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Elicio Therapeutics, Inc. - Common Stock (NQ:ELTX)

10.11 +0.17 (+1.69%)
Streaming Delayed Price Updated: 10:56 AM EDT, Aug 15, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Elicio Therapeutics, Inc. - Common Stock

< Previous 1 2 3 4 Next >
12 Health Care Stocks Moving In Monday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Friday's After-Market Session
 
Via Benzinga
Elicio Therapeutics to Present ELI-002 7P (AMPLIFY-7P) Trial in Progress Poster on Phase 1/2 Study of Lymph Node-Targeted Vaccine at ASCO GI Symposium
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics to Present at the B. Riley Securities 4th Annual Oncology Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Benzinga's 'Stock Whisper' Index: 5 Stocks Investors Secretly Monitor But Don't Talk About Yet
A look at five stocks seeing increased attention from investors. 
Via Benzinga
Elicio Therapeutics Announces First Patient Dosed in Randomized Phase 2 Pancreatic Cancer Study
From Elicio Therapeutics Inc.
Via GlobeNewswire
Unity Layoffs 2024: What to Know About the Latest U Job Cuts
Unity layoffs are on the way as the video game software company reveals plans to cut 1,800 jobs to focus on its core business. 
Via InvestorPlace
Topics Workforce
Why Is Cyclacel Pharmaceuticals (CYCC) Stock Down 9% Today?
Cyclacel Pharmaceuticals stock is slipping on Tuesday after shares of CYCC rallied on Monday alongside it regaining Nasdaq compliance. 
Via InvestorPlace
Why Is Grifols (GRFS) Stock Down 38% Today?
Grifols stock is falling hard as investors sell GRFS shares after the company was hit with a short report from Gotham City Research. 
Via InvestorPlace
Why Is Elicio Therapeutics (ELTX) Stock Up 11% Today?
Elicio Therapeutics stock is up with heavy trading of ELTX shares are posting positive preliminary results from a Phase 1 clinical trial. 
Via InvestorPlace
12 Health Care Stocks Moving In Tuesday's Pre-Market Session
 
Via Benzinga
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Tuesday
Pre-market stock movers are worth checking out on Tuesday to catch up on all of the hottest stock market news for this morning! 
Via InvestorPlace
Nature Medicine Publishes Updated Preliminary Phase 1 Data From Elicio Therapeutic’s AMPLIFY-201 Phase 1 Solid Tumor Study of ELI-002
From Elicio Therapeutics Inc.
Via GlobeNewswire
12 Health Care Stocks Moving In Wednesday's Intraday Session
 
Via Benzinga
12 Health Care Stocks Moving In Monday's Pre-Market Session
 
Via Benzinga
Why SoFi Technologies Shares Are Trading Lower By Around 13%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of SoFi Technologies, Inc. (NASDAQ: SOFI) fell sharply during Wednesday’s session after Keefe, Bruyette & Woods downgraded rating on the stock. 
Via Benzinga
Why Reneo Pharmaceuticals Shares Are Trading Higher By Around 14%? Here Are Other Stocks Moving In Wednesday's Mid-Day Session
Shares of Reneo Pharmaceuticals, Inc. (NASDAQ: RPHM) shares rose sharply during Wednesday’s session after Concentra sent an acquisition proposal to acquire 100% of equity of the company for $1.80 per... 
Via Benzinga
Over $2M Bet On This Energy Stock? Check Out These 3 Stocks Insiders Are Buying
Although U.S. stocks closed higher on Tuesday, there were a few notable insider trades. 
Via Benzinga
Elicio Therapeutics Announces $7.0 Million Private Placement Financing
From Elicio Therapeutics Inc.
Via GlobeNewswire
A Look At Elicio Therapeutics’ (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?
--News Direct-- 
Via News Direct
A Look At Elicio Therapeutics' (NASDAQ: ELTX) Pipeline: What Does This Cancer-Fighting Company Have In Store For The Future?
Elicio Therapeutics Inc. (NYSE: ELTX) is using precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and solid tumors. 
Via Benzinga
Elicio Therapeutics to Present at the H.C. Wainwright 4th Annual Precision Oncology Virtual Conference
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Reports Third Quarter 2023 Financial Results and Provides Corporate Updates
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Immunogenicity Data from the Ongoing Phase 1 Study of ELI-002 and New Preclinical Data on ELI-007 and ELI-008 at the Society for Immunotherapy of Cancer (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System
--News Direct-- 
Via News Direct
Elicio Therapeutics (NASDAQ: ELTX) Reports Promising Progress In Cancer Vaccine Clinical Trials, Placing An Emphasis On The Lymphatic System
An estimated 609,820 people will die of cancer in the United States this year, according to the National Cancer Institute. Promising results from a 12-year-old clinical-stage biotechnology company have... 
Via Benzinga
How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030
--News Direct-- 
Via News Direct
How Elicio Therapeutics Is Taking A Different Approach To Treating Cancers Like Colon Cancer, Expected To Be The Leading Killer Cancer By 2030
Founded in 2011, Elicio Therapeutics Inc. (NASDAQ: ELTX) strives to use precision vaccines, immunomodulators and cell-based therapies to assemble cancer-killing immune responses against both blood and... 
Via Benzinga
Elicio Therapeutics Announces Upcoming Presentations at the Society for Immunotherapy of Cancer’s (SITC 2023) Annual Meeting
From Elicio Therapeutics Inc.
Via GlobeNewswire
Elicio Therapeutics Presents Updated Preliminary Data Including Promising Relapse-Free Survival Data from the Phase 1 Study of ELI-002 at AACR Special Conference: Pancreatic Cancer
From Elicio Therapeutics Inc.
Via GlobeNewswire
< Previous 1 2 3 4 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms Of Service.